Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Upstream Bio is a clinical-stage biopharmaceutical company developing verekitug, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) for severe asthma and atopic dermatitis. The company is pre-revenue with a single lead asset in Phase 2b/3 development, competing against established TSLP inhibitors like Tezspire (AstraZeneca/Amgen). The stock trades on binary clinical trial outcomes and partnership potential, with significant cash burn requiring future financing.
Upstream Bio operates a classic biotech development model: raise capital through equity offerings, invest in clinical trials to demonstrate safety/efficacy, then either commercialize independently or partner with larger pharma for milestone payments and royalties. Verekitug differentiates through subcutaneous dosing convenience and potential best-in-class TSLP inhibition profile. Pricing power depends on demonstrating superiority or non-inferiority to Tezspire in head-to-head studies, with severe asthma biologics typically priced $30,000-$40,000 annually. The company has no manufacturing infrastructure and will rely on contract manufacturing organizations (CMOs).
Phase 2b/3 clinical trial data readouts for verekitug in severe asthma - primary endpoint achievement drives 50-100% moves
FDA regulatory milestone announcements (IND clearances, breakthrough therapy designation, BLA submission timing)
Strategic partnership or licensing deal announcements with big pharma (validates asset, provides non-dilutive funding)
Equity financing announcements and terms (dilution concerns given cash burn rate)
Competitive TSLP inhibitor data from AstraZeneca/Amgen (Tezspire) or other pipeline assets affecting market opportunity perception
Single-asset dependency - verekitug represents 100% of enterprise value with no pipeline diversification; clinical failure creates total loss scenario
Established competition from Tezspire (approved 2021, $500M+ annual sales trajectory) and potential biosimilars post-2030 compress market opportunity and pricing power
Regulatory pathway uncertainty for demonstrating differentiation versus approved TSLP inhibitors; FDA may require head-to-head superiority trials rather than non-inferiority
AstraZeneca/Amgen's Tezspire has first-mover advantage with established payer relationships, physician familiarity, and expanding label (COPD, chronic rhinosinusitis indications in development)
Oral TSLP inhibitors in earlier development could offer superior convenience versus subcutaneous biologics, though 5+ years from market
Big pharma competitors (GSK, Sanofi, Regeneron) have diversified respiratory portfolios and can bundle pricing, limiting Upstream Bio's negotiating leverage as monoproduct company
Cash burn rate of $100M+ annually with zero revenue creates financing dependency; current cash covers approximately 12-18 months at stated burn rate
Equity dilution risk from future capital raises - at $400M market cap, raising $150-200M for Phase 3 completion would dilute existing shareholders 35-50%
No debt capacity given pre-revenue status limits financing flexibility to equity or dilutive convertible structures
low - Clinical-stage biotech valuations are driven by binary scientific outcomes rather than GDP or consumer spending. However, severe economic downturns can constrain venture capital and public market financing availability, creating liquidity risk for cash-burning companies. Patient enrollment in clinical trials shows minimal cyclical sensitivity as severe asthma patients seek treatment regardless of economic conditions.
Rising interest rates negatively impact Upstream Bio through two channels: (1) Higher discount rates compress NPV of distant future cash flows, disproportionately affecting pre-revenue biotechs with 5-7 year commercialization timelines. (2) Risk-free rate competition makes speculative biotech investments less attractive versus safer fixed income alternatives. The 10-year Treasury yield directly influences biotech sector valuation multiples. Additionally, higher rates increase the cost of convertible debt financing if the company pursues non-equity capital raises.
Minimal direct credit exposure - Upstream Bio has zero debt (Debt/Equity: 0.00) and operates with equity financing. However, tightening credit conditions indirectly affect the company by constraining IPO markets and follow-on offering appetite, potentially forcing financing at unfavorable terms. Venture debt availability for bridge financing also correlates with broader credit conditions.
growth - Upstream Bio attracts speculative biotech investors seeking asymmetric risk/reward from binary clinical catalysts. The -67.6% three-month return reflects typical pre-revenue biotech volatility around data readouts or financing events. Value investors avoid due to negative earnings and cash burn. No dividend. Momentum traders enter around clinical trial data announcement dates. Institutional ownership skews toward specialized healthcare hedge funds and venture capital crossover funds rather than broad index investors.
high - Clinical-stage single-asset biotechs exhibit extreme volatility with 50-100% single-day moves on trial results. The -67.6% quarterly decline and -54.1% six-month performance demonstrate downside volatility from either negative clinical data or financing concerns. Implied volatility typically exceeds 80-100% around data catalyst dates. Low float and limited institutional coverage amplify price swings on modest volume.
